Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus XHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus XHANCE.
BREO ELLIPTA vs XHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid